Abstract
Objectives: To evaluate the effects of the single-nucleotide polymorphism (SNP) rs1800795 in interieukin-6 (IL-6) gene on diabetic microvascular complications of Type 2 diabetes mellitus (T2DM), using statistical meta-analysis.Methods: Literature pertaining to the relationship between the SNP rs1800795 and microvascular complications of T2DM including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and foot disease was retrieved from PubMed, Web of Science Knowledge and SinoMed databases. Original information was analyzed using Stata 12.0, including meta-analysis statistics, test for heterogeneity, evaluation of publication bias and sensitivity. Subgroup analysis was conducted to assess the effect of specific factors on the corresponding results.Results: In total, 14 eligible articles were obtained. The SNP rs1800795 in IL-6 gene is not correlated with risk of microvascular complications in T2DM. Among the original literature, a genetic model (OR = 1.071, 95% CI: 0.681–1.685, P=0.767), an allelic genetic model (OR = 1.010, 95% CI: 0.959–1.063, P=0.703), a heterozygote genetic model (OR = 1.107, 95% CI: 0.916–1.339, P=0.292), a dominant genetic model (OR = 1.108, 95% CI: 0.885–1.387, P=0.372), and a recessive genetic model (OR = 0.978, 95% CI: 0.646–1.478, P=0.917) were included respectively. In the subgroup analysis by types of diabetic microvascular complications, we found no correlation between the SNP rs1000795 polymorphism and complications of T2DM in either the homozygote genetic model or the allelic genetic model (P<0.05).Conclusion: Our results demonstrate that rs1800795 polymorphism in IL-6 gene is not correlated with the susceptibility of microvascular complications of T2DM.
Highlights
Diabetes mellitus (DM) is a chronic metabolic disease
We found that there was a lack of association between the risk of diabetic microvascular complications in Type 2 diabetes mellitus (T2DM) and a homozygote genetic model (OR = 1.071, 95% CI: 0.681–1.685, P=0.767), an allelic genetic model (OR = 1.010, 95% CI: 0.959–1.063, P=0.703), a heterozygote genetic
Our results showed that there was no correlation between risk of diabetic microvascular complications in T2DM and a homozygote genetic model (OR = 1.071, 95%CI: 0.681–1.685, P=0.767), an allelic genetic model (OR = 1.010, 95% CI: 0.959–1.063, P=0.703), a heterozygote model (OR = 1.107, 95% CI: 0.916–1.339, P=0.292), a dominant genetic model (OR = 1.108, 95% CI: 0.885–1.387, P=0.372), and a recessive model (OR = 0.978, 95% CI: 0.646–1.478, P=0.917), respectively
Summary
Diabetes mellitus (DM) is a chronic metabolic disease. Over 382 million people worldwide have DM, the prevalence of Type 2 diabetes mellitus (T2DM) in children and adolescents is on the rising around the world, in parallel with the increase in the rate of obesity [1]. DM might become the seventh leading cause of death in humans by 2030 [2]. DM is associated with microvascular and macrovascular complications, which are considered one of the major causes of morbidity and mortality. Especially microvascular complications (diabetic retinopathy, nephropathy, foot disease, and neuropathy) are the major dangerous outcome of this disease. Chronic inflammatory processes are involved in the development of diabetic microvascular complications. Inflammatory cytokines including interleukin-6 (IL-6) play an important role in the pathogenesis of T2DM and its complications [3]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
